medRxiv is receiving many new papers on coronavirus SARS-CoV-2.   A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,314 Articles (22,772 medRxiv, 8,542 bioRxiv)

Most recent first Previous |  Page 995: Articles 9941-9950  | Next

Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
Bruhn-Olszewska, B., Davies, H., Sarkisyan, D., Juhas, U., Rychlicka-Buniowska, E., Wojcik, M., Horbacz, M., Jakalski, M., Olszewski, P., Westholm, J. O., Smialowska, A., Wierzba, K., Torinsson Naluai, A., Jern, N., Andersson, L.-M., Jarhult, J., Filipowicz, N., Tiensuu Janson, E., Rubertsson, S., Lipcsey, M., Gisslen, M., Hultstrom, M., Frithiof, R., Dumanski, J. P.
10.1101/2022.01.19.22269521 — Posted: 2022-01-19
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
Sims, J. J., Lian, S., Wilson, J. M.
10.1101/2022.01.17.476672 — Posted: 2022-01-19
Differences in environmental stability among SARS-CoV-2 variants of concern: Omicron has higher stability
Hirose, R., Itoh, Y., Ikegaya, H., Miyazaki, H., Watanabe, N., Yoshida, T., Bandou, R., Daidoji, T., Nakaya, T.
10.1101/2022.01.18.476607 — Posted: 2022-01-19 Discussion: Onsite
Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant
Rosales, R., McGovern, B. L., Rodriquez, M. L., Rai, D. K., Cardin, R. D., Anderson, A. S., Sordillo, E. M., van Bakel, H., Simon, V., Garcia-Sastre, A., White, K. M.
10.1101/2022.01.17.476685 — Posted: 2022-01-19
Prediction and validation of host cleavage targets of SARS-CoV-2 3C like protease
Yucel, N., Marchiano, S., Tchelepi, E., McAfee, Q., Nimmagadda, N., Ren, A., Shi, S., Murry, C. E., Arany, Z.
10.1101/2022.01.17.476677 — Posted: 2022-01-19
Cross-sectional study to assess the efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies
Abella, E., Trigueros, M., Pradenas, E., Munoz Lopez, F., Garcia Pallarols, F., Ben Azaiz Ben Lahsen, R., Trinite, B., Urrea, V., Marfil, S., Rovirosa, C., Puig, T., Grau, E., Chamorro, A., Toledo, R., Font, M., Palacin, D., Lopez Segui, F., Carrillo, J., Prat, N., Mateu, L., Clotet, B., Blanco, J., Massanella, M.
10.1101/2022.01.19.22269531 — Posted: 2022-01-19
Serum extracellular vesicles trace COVID-19 progression and immune responses
Yim, K. H. W., Borgoni, S., Chahwan, R.
10.1101/2022.01.19.22269529 — Posted: 2022-01-19
ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-19
Pietzner, M., Chua, R. L., Wheeler, E., Jechow, K., Radbruch, H., Trump, S., Heidecker, B., Heppner, F., Eils, R., Mall, M., Sander, L. E., Lehmann, I., Lukassen, S., Wareham, N. J., Conrad, C., Langenberg, C.
10.1101/2022.01.17.22269283 — Posted: 2022-01-19
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern
Rai, D. K., Yurgelonis, I., McMonagle, P., Rothan, H. A., Hao, L., Gribenko, A., Titova, E., Kreiswirth, B., White, K. M., Zhu, Y., Anderson, A. S., Cardin, R. D.
10.1101/2022.01.17.476644 — Posted: 2022-01-19
Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2
Greasley, S. E., Noell, S., Plotnikova, O., Ferre, R. A., Liu, W., Bolanos, B., Fennell, K. F., Nicki, J., Craig, T., Zhu, Y., Stewart, A. E., Steppan, C. M.
10.1101/2022.01.17.476556 — Posted: 2022-01-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.